# Microfluidic vortex shedding: a low-cost, high efficiency method for genetic modification to support cell engineering for cell-based immunotherapies

> **NIH NIH N43** · INDEE, INC · 2020 · $399,299

## Abstract

Personalized gene-modified cell immunotherapies exist, but manufacturing has yet to be optimized to increase the broad availability of these life-saving therapies to patients in need. This proposal is focused on meeting this need with the continued development of microfluidic vortex shedding (μVS), a safe and rapid approach to genetically modify patient-derived immune cells. The long term objective of this proposal is to integrate μVS into the manufacturing workflow of cell-based cancer immunotherapies. The goal of this contract proposal to demonstrate the feasibility of μVS technology in generating representative Chimeric Antigen Receptor T cells (CAR-T) and T Cell Receptor T cells (TCR-T) cells. The research and development objectives are to: (1) demonstrate the technical performance of μVS transfection of primary T cells with clinically relevant CAR and TCR constructs, and (2) demonstrate the functionality and safety of transfected T cells generated by μVS in cell based assays. Pending the successful completion of these objectives, CAR-T and TCR-T cells will be engineered using patient-derived T cells, and commercial-scale processing and enrichment of sufficient genetically modified viable cells for clinical applications will be demonstrated.

## Key facts

- **NIH application ID:** 10260803
- **Project number:** 75N91020C00030-0-9999-1
- **Recipient organization:** INDEE, INC
- **Principal Investigator:** JUSTIN JARRELL
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $399,299
- **Award type:** —
- **Project period:** 2020-09-08 → 2021-06-07

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10260803

## Citation

> US National Institutes of Health, RePORTER application 10260803, Microfluidic vortex shedding: a low-cost, high efficiency method for genetic modification to support cell engineering for cell-based immunotherapies (75N91020C00030-0-9999-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10260803. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*